NSP1 found to act as an immune evasion factor in SARS-CoV-2 infections

NewsGuard 100/100 Score

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a major blip in the health, societal and economic well-being of the whole world for more than two years, following its unexpected emergence in December 2019.

This beta-coronavirus undergoes transcription in the host cell, giving rise to multiple polyproteins that are cleaved by viral proteases to yield structural and non-structural proteins.

Study: Parsing the role of NSP1 in SARS-CoV-2 infection. Image Credit: ThSucho/Shutterstock
Study: Parsing the role of NSP1 in SARS-CoV-2 infection. Image Credit: ThSucho/Shutterstock

A new study explores the role of non-structural protein 1 (NSP1) in SARS-CoV-2 infection and pathogenesis.


Viruses are obligate intracellular parasites, and hijack the host cell machinery to translate their own genetic code into proteins to drive further steps in replication and propagation of infection. Typically, they shut down host protein translation, which is also called “host shutoff”. This could help take over the cell by rerouting the protein translation machinery away from cellular messenger ribonucleic acid (mRNA) towards viral mRNAs, while simultaneously helping evade the host cell’s immune response targeting the virus.

Many strategies are used by viruses to achieve host shutoff, including direct blockade of translation, as well as indirect methods like disruption of the transcription and trafficking of mRNA from the nucleus to the cytoplasm, and inducing the breakdown of mRNA. In particular, coronaviruses (CoVs) have been studied for this aspect.

The authors of this study had already shown that all three of the mechanisms listed above are operative in SARS-CoV-2 infection. Interestingly, NSP1 is the best understood host shutoff factor, and is also crucial in the pathogenesis of betaCoVs.

The earlier SARS-CoV pathogen’s NSP1 was shown in prior experiments to block host protein translation via a number of mechanisms, including blocking the entry channel of the mRNA, suppressing the export of cellular mRNAs, and enhancing cellular mRNA breakdown. This latter does not affect viral proteins because of the 5’ leader sequences, though the interactions between each of these processes can lead to indirect effects on each of the others.

In the current paper, published in the journal Cell Reports, NSP1 mutants were overexpressed to understand how this protein affects the expression of cellular genes.


The researchers found that NSP1 acts on the host cell by increasing the rate of breakdown of cellular mRNAs, while blocking translation of host proteins at the same time. The wildtype NSP1 causes cellular mRNAs to undergo endonucleolytic cleavage, predisposing them to their breakdown. Both these processes appear to be dependent on ribosome binding by the NSP1, as is the case with SARS-CoV.

Moreover, mutant NSP1 retained the ability to block host RNA translation, but lost its capacity to accelerate RNA breakdown, indicating that these two processes occur distinctly. NSP1 also seems to inhibit its own expression.

NSP1 also interacts with the NXF1 protein via its N-terminal region, causing interference with the export of nuclear mRNA. The location of this interaction seems to indicate that it is independent of the earlier-described ribosome-NSP1 binding. That is, NSP1 is “is able to target three distinct steps in the mRNA biogenesis pathway.”

Another finding was that NSP1 induces the breakdown of cytosolic RNA within the infected cells, as indicated by a major decrease in the half-lives of the cytoplasmic transcripts that are bound to the ribosome, vs the nuclear transcripts. This is not related to the suppression of nuclear RNA export.

The induction of a mutant NSP1, with the deletion of amino acids 155–165, did not reduce the expression of the protein, but the mutant seemed to show stronger binding to the nuclear RNA export proteins. However, when the wildtype and mutant SARS-CoV-2 viruses were allowed to infect cells with an interferon (IFN) antiviral response in operation, the mutant virus showed attenuated growth compared to the other, over a prolonged period of observation.

The reduced expression of viral genes could perhaps be the result of NSP1 interference with the interferon response, since the IFN-stimulated genes (ISGs) were more strongly induced in the mutant-infected cells compared to the wildtype infected cells. That is, the inhibition in the growth of the mutant-infected cells was caused by the increased strength of the antiviral type I IFN response, as exemplified by the higher IFNꞵ protein levels compared to those in the cells infected by the wildtype virus.

Again, the selective JAK-STAT inhibitor ruxolitinib, which suppresses IFN pathways, rescued the mutant virus from its replication blockade.

These results demonstrate that an enhanced IFN response in cells infected with CoV2-mut is responsible for its impaired propagation.”

The study also showed that NSP1 is the chief driver of host shutoff following SARS-CoV-2 infection, via its engagement with the ribosomes. The viral genes also showed a low translation efficiency (TE), comparable to that of the lower end of cellular genes. This was thought to be possibly due to the cloistering of large quantities of viral RNA within the replication compartments where ribosomes could not access them.

The TEs of viral genes were further impacted by the presence of the mutation in NSP1, indicating that the wildtype NSP1 increases viral protein synthesis via its ribosome engagement. Yet, protein translation levels are reduced by a factor of four in wildtype-infected cells vs mutant-infected cells. This suggests strongly that the mutant NSP1 yields comparable or higher levels of translation compared to the wildtype protein.

The mutant NSP1 allows for viral RNA to be produced at unchanged levels, but without shutoff of host RNA. However, cytosolic transcripts were found to be reduced more strongly with the wildtype virus compared to NSP1 mutants. The half-life of these cytosolic transcripts was also lower. This points to NSP1-dependent degradation of cellular transcripts, mediated by NSP1-ribosome binding.

This is supported by the increase in intronic reads with wildtype SARS-CoV-2 infection compared to mutant infection, attributable to the higher rate of breakdown of mature cytosolic RNAs following infection.

In vivo hamster studies also showed that the NSP1 mutant did not cause a marked loss of weight following infection, unlike the wildtype virus, indicating the key pathogenetic role of the protein. Within a week of infection, body weight dropped significantly, while viral titers in the lungs and nasal mucosa were higher, in those infected by the wildtype virus compared to the mutant. As expected, ISGs were upregulated in the lungs of the latter, and cytosolic RNAs were expressed at lower levels.


This striking study brings out the central role of NSP1 in shutting off protein synthesis following SARS-CoV-2 infection, and reveals three key mechanisms of action. Of these, RNA breakdown and inhibition of translation seem to be the result of its interaction with ribosomes, while in contrast, its inhibition of nuclear RNA export is independent of ribosome binding.

Viral genes escape NSP1-dependent inhibition of translation of both viral and cellular mRNAs. However, since the latter are broken down by NSP1, available ribosomes now translate only viral RNAs. Alternatively, or in addition, viral mRNAs might resist suppression by NSP1 because of the conformational change they induce in this protein following binding, freeing the ribosome entry channel.

The host shutoff may enhance viral propagation, both increasing the translation of viral proteins and suppressing the antiviral response of the host cell. The findings of this study indicate that the latter is the more important of the two actions, since the antiviral type I IFN response, and increase in ISG response, within infected cells and hamsters, led to the attenuation of growth of the mutant virus, even without host shutoff.  

Overall, our data establish that nsp1 is a major immune evasion factor of SARS-CoV-2.”

Journal reference:
Dr. Liji Thomas

Written by

Dr. Liji Thomas

Dr. Liji Thomas is an OB-GYN, who graduated from the Government Medical College, University of Calicut, Kerala, in 2001. Liji practiced as a full-time consultant in obstetrics/gynecology in a private hospital for a few years following her graduation. She has counseled hundreds of patients facing issues from pregnancy-related problems and infertility, and has been in charge of over 2,000 deliveries, striving always to achieve a normal delivery rather than operative.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, Liji. (2022, June 16). NSP1 found to act as an immune evasion factor in SARS-CoV-2 infections. News-Medical. Retrieved on May 22, 2024 from https://www.news-medical.net/news/20220616/NSP1-found-to-act-as-an-immune-evasion-factor-in-SARS-CoV-2-infections.aspx.

  • MLA

    Thomas, Liji. "NSP1 found to act as an immune evasion factor in SARS-CoV-2 infections". News-Medical. 22 May 2024. <https://www.news-medical.net/news/20220616/NSP1-found-to-act-as-an-immune-evasion-factor-in-SARS-CoV-2-infections.aspx>.

  • Chicago

    Thomas, Liji. "NSP1 found to act as an immune evasion factor in SARS-CoV-2 infections". News-Medical. https://www.news-medical.net/news/20220616/NSP1-found-to-act-as-an-immune-evasion-factor-in-SARS-CoV-2-infections.aspx. (accessed May 22, 2024).

  • Harvard

    Thomas, Liji. 2022. NSP1 found to act as an immune evasion factor in SARS-CoV-2 infections. News-Medical, viewed 22 May 2024, https://www.news-medical.net/news/20220616/NSP1-found-to-act-as-an-immune-evasion-factor-in-SARS-CoV-2-infections.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel bispecific antibodies show promise against evolving SARS-CoV-2 variants